MTOR and breast carcinoma: It was reported that mTOR signaling is dysregulated in breast cancer patients following abemaciclib treatment (70) and PI3K/mTOR pathway has been shown to be upregulated in response to chronic exposure to CDK4/6 inhibitors (71).